BioPharma Reporter

SEPTEMBER 5, 2024

In one of the largest cell and gene therapy funding rounds this year, the US company Arsenal Biosciences has secured $325 million in a Series C round to bankroll T cell therapies engineered to take on solid tumors.

Engineer 52

Engineer Gene Therapy Development Gene 52

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Engineer 262

Engineer Vaccination Vaccine Clinical Trials 262

pharmaphorum

JUNE 15, 2021

When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. . The post Biogen’s ambitions in gene therapy hit by another failed pivotal trial appeared first on.

Gene Therapy 105

Gene Therapy Gene Trials Genetics 105

pharmaphorum

OCTOBER 22, 2020

Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high-profile life sciences investors. That means replacing the defective gene with a working copy should – or correcting it in situ – could stop the disease in its tracks.

Gene Therapy 98

Gene Therapy Gene Life Science Engineer 98

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Companies Offering Bioassay Services for Cell and Gene Therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

BioTech 365

JANUARY 19, 2022

64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing 64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing Multibillion-dollar gene therapy market … Continue reading →

Gene Therapy 52

Gene Therapy Engineer Gene Manufacturing 52

Pharmaceutical Technology

NOVEMBER 16, 2022

ElevateBio has entered a partnership with Affini-T Therapeutics to progress the latter’s engineered TCR-T therapies focused on Kirsten rat sarcoma viral oncogene homolog (KRAS), a dominant oncogenic driver mutation in solid tumours. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

STAT News

JULY 11, 2022

Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.

Gene 111

Gene Gene Therapy Genetic Engineering Engineer 111

BioSpace

MAY 10, 2021

Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.

Gene Therapy 52

Gene Therapy Gene Engineer Genetics 52

BioTech 365

OCTOBER 27, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ElevateBio cuts a deal for Life Edit, adding genome engineering tech to support gene therapy pipeline.ElevateBio cuts a deal for Life Edit, adding genome engineering tech to … Continue reading →

Gene Therapy 40

Gene Therapy Engineer Genome Genomics 40

Scienmag

JUNE 9, 2021

Credit: RCSI Scientists have developed polypeptide-based materials that act as effective vectors for delivering gene therapies. The first-of-its-kind platform enables the vectors to be adapted to suit the specific gene therapy cargo.

Gene Therapy 53

Gene Therapy Gene Scientist Medicine 53

BioPharma Reporter

APRIL 11, 2023

Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.

Gene Therapy 98

Gene Therapy Gene Engineer Regulation 98

XTalks

MAY 22, 2024

In this episode, Ayesha spoke with John Finn, PhD, Chief Scientific Officer at Tome Biosciences , a company developing programmable gene insertion (PGI) technology. PGI is a cutting-edge gene editing technology that allows for the insertion of large sequences of DNA with site-specific precision.

Gene Editing 52

Gene Editing Life Science Gene Gene Therapy 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

STAT News

AUGUST 18, 2022

The therapy, Zynteglo, is just the third gene therapy approved by the FDA, and the first to target a chronic blood disease. It uses an engineered virus to deliver a gene fix into the bone marrow of patients. Zynteglo will cost $2.8

Gene Therapy 98

Gene Therapy Gene FDA Approval Pharmacy 98

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

The Pharma Data

JANUARY 25, 2021

a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) — Ambulero, Inc. ,

Gene Therapy 52

Gene Therapy Gene Engineer Licensing 52

The Pharma Data

AUGUST 24, 2020

The FDA has approved a request from American Gene Technologies to begin a clinical study into its HIV gene therapy. This requires an 11-day programme which involves extracting blood from an HIV patient and separating their T cells, which are then engineered in a lab to make them immune to HIV. Conor Kavanagh.

Gene Therapy 52

Gene Therapy Gene FDA Approval Trials 52

Scienmag

FEBRUARY 4, 2022

Biomedical engineers at Duke University have demonstrated a gene therapy that helps heart muscle cells electrically activate in live mice. DURHAM, N.C.

Gene 72

Gene Bacteria Gene Therapy Engineer 72

The Pharma Data

OCTOBER 18, 2020

In late August, Pfizer announced it was investing an additional $500 million into its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. Ricci told BioSpace the company has been “investing heavily in gene therapy and in the Raleigh-Durham Research Triangle Park area.”

Gene Therapy 52

Gene Therapy Gene HR Manufacturing 52

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. CircAde is said to be the most advanced therapeutic concept, and leverages the company’s experience in oncolytic viruses to use engineered adenoviruses to deliver circRNA to cancer cells.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. This increases the expression of fetal haemoglobin.

Gene Therapy 264

Gene Therapy Drugs Gene Gene Editing 264

Pharmaceutical Technology

APRIL 14, 2023

The company can use its mammalian cell engineering expertise and capabilities to screen CAR T-cells, to discover and optimise next-generation therapeutic candidates for its partners. WARF and Ginkgo Bioworks also intend to partner on developing a pooled in vivo screening platform to further advance the discovery of new CAR therapies.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. There is significant unmet medical need for a sustained therapy to treat eye diseases. MUNICH, Germany, Jan.

Gene Therapy 52

Gene Therapy Gene Research Protein 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

Pharmaceutical Technology

AUGUST 26, 2022

ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Pharmaceutical Technology

MARCH 29, 2023

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases. The two companies will together research and develop T cell therapies for Crohn’s disease and ulcerative colitis, as well as two other undisclosed indications.

Development 245

Development Gene Therapy Gene Production 245

Scienmag

OCTOBER 19, 2020

New generation CRISPR technology lays foundation for therapeutics to treat a wide range of inherited ocular diseases Credit: Nature Biomedical Engineering Irvine, CA – October 19, 2020 – A breakthrough study, led by researchers from the University of California, Irvine, results in the restoration of retinal and visual functions of mice (..)

Gene Therapy 98

Gene Therapy Gene Engineer Research 98

Scienmag

JUNE 2, 2021

Researchers create novel CRISPR-based fly species as a new method of controlling gene drive spread Credit: Akbari lab, UC San Diego CRISPR-based technologies offer enormous potential to benefit human health and safety, from disease eradication to fortified food supplies.

Gene 98

Gene Engineer Development Research 98

BioSpace

FEBRUARY 2, 2021

The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.

Engineer 51

Engineer Gene Therapy Gene 51

Pharmaceutical Technology

MAY 3, 2023

BrightPath Biotherapeutics CEO Kenichi Nagai stated: “This collaboration with Artisan provides us with the potential to create highly engineered allogeneic iNKT cellular therapy programmes for a range of indications, including solid tumours. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Engineer Development 130

Pharmaceutical Technology

MAY 31, 2023

This includes targets found in several tumours, common driver mutations, and latent viral genes. The company is also looking at developing therapies based on individual patient neoantigens in patient human leukocyte antigens (HLAs). Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Engineer Vaccination 130

Pharmaceutical Technology

JUNE 12, 2023

Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Engineer 130

Engineer Gene Therapy Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 5, 2023

But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. More broadly however, several advancements are on the horizon for cell and gene therapies in 2023. AZ: Cell and gene therapies often come with a high price.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The post AstraZeneca pays record 660% premium for gene editing company LogicBio appeared first on.

Gene Editing 64

Gene Editing Gene Genome Genomics 64